SCHEMBL2811663

SCHEMBL2811663

Cc1ncc(C(=O)NC2(C(=O)NCc3ccc(Nc4ccc(F)cc4C(F)(F)F)cn3)CC2)s1

nearest known ligand 0.36

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
AR P10275 1/20 0.36
CNR2 P34972 2/20 0.34
TRPA1 O75762 4/20 0.34
FPR2 P25090 1/20 0.34
GRM5 P41594 1/20 0.34
P2RX7 Q99572 2/20 0.34
PTK2 Q05397 2/20 0.33
BACE1 P56817 1/20 0.33
BDKRB1 P46663 1/20 0.33
AURKA O14965 2/20 0.33
NTRK1 P04629 1/20 0.33
HDAC3 O15379 1/20 0.33
HDAC1 Q13547 1/20 0.33
HDAC2 Q92769 1/20 0.33
HDAC6 Q9UBN7 1/20 0.33
OPRL1 P41146 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2809241 0.91 CNR2 (0.35) CNR2TRPA1P2RX7PTK2BACE1
SCHEMBL2813235 0.89 OGA (0.34) CNR2TRPA1P2RX7AURKAHDAC3
SCHEMBL14856796 0.88 TRPA1 (0.33) CNR2TRPA1P2RX7BACE1BDKRB1
SCHEMBL2812751 0.88 P2RX7 (0.37) CNR2TRPA1P2RX7AURKANTRK1
SCHEMBL2811921 0.88 HDAC3 (0.38) CNR2TRPA1P2RX7PTK2BDKRB1
SCHEMBL186050 0.86 CNR1 (0.36) CNR2TRPA1GRM5P2RX7PTK2
SCHEMBL2806201 0.86 NPC1 (0.36) CNR2TRPA1P2RX7PTK2BACE1
SCHEMBL185916 0.85 BDKRB1 (0.41) CNR2TRPA1FPR2P2RX7PTK2
SCHEMBL2807486 0.85 HDAC3 (0.41) CNR2TRPA1P2RX7BDKRB1AURKA
SCHEMBL2805859 0.85 BDKRB1 (0.41) ARCNR2TRPA1P2RX7BDKRB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
US-20130131075-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-05-23 US disclosed
EP-2401256-B1 Compounds as bradykinin B1 antagonists BOEHRINGER INGELHEIM INT (DE) 2013-04-17 EP disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
US-20100240669-A1 NEW COMPOUNDS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-23 US disclosed
WO-2010097372-A1 COMPOUNDS AS BRADYKININ B1 ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-09-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130131075-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 AR 1452/4885CNR2 882/4885TRPA1 552/4885
US-20100240669-A1 NEW COMPOUNDS ADORA1, H1-10, P2RY11 AR 1452/4885CNR2 882/4885TRPA1 552/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.